SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is gaining traction as investors anticipate its expansion to the Ethereum mainnet and the potential impact of new predictive allocation features. Community members are actively debating the stock's long-term utility within the Base ecosystem, with many viewing current price levels as an accumulation opportunity despite ongoing market volatility.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

Serve Robotics is capturing investor attention as the company scales its autonomous sidewalk delivery fleet and expands into new verticals like healthcare logistics, leading many in the community to weigh its long-term potential against heavy short interest and ongoing dilution concerns. The stock remains a major focal point for traders tracking the broader robotics theme, with participants actively debating the impact of upcoming earnings and the potential for a technical breakout driven by its strategic partnerships.

JetBlue Airways Corp. engages in the provision of air transportation services. Its brands include jetBlue, jetBlue Vacations, Paisly, and TrueBlue. It operates through the following geographic segments: Domestic and Canada, Caribbean and Latin America, and Atlantic. The company was founded by David Gary Neeleman in August 1998 and is headquartered in Long Island City, NY.

Jetblue Airways Corp

JetBlue is experiencing significant market volatility and trading volume as investors react to reports that the company has retained financial advisors to explore potential strategic alternatives, including a possible sale or merger. While the stock initially surged on rumors of acquisition interest from major carriers, community discussion remains polarized between those speculating on a lucrative buyout premium and skeptics who highlight the airline's debt load, persistent operating pressures, and regulatory hurdles in the current antitrust environment.

TokenOS is the world’s most advanced AI-powered Web3 development platform, designed to turn natural language prompts into fully functional, production-ready blockchain applications. From simple tokens and memecoins to complex DeFi protocols, TokenOS automates the creation, deployment, and auditing of smart contracts and dApps with enterprise-grade reliability. By combining advanced language models with blockchain infrastructure, TokenOS removes the barriers of technical expertise, making Web3 development accessible to everyone. With instant deployment, built-in security best practices, and cross-chain support on the roadmap, TokenOS empowers entrepreneurs, developers, and creators to launch tokenized businesses and decentralized applications in seconds.

TokenOS AI

TokenOS AI (TOS) is gaining significant traction as investors rally around its recent v4 launch and a new revenue-sharing model that rewards stakers and node runners through its decentralized GPU compute network. Community sentiment remains highly bullish, driven by the scarcity of available supply as a massive percentage of tokens is locked in long-term staking.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is seeing significant investor attention following promising long-term maintenance data for rezpegaldesleukin in atopic dermatitis and anticipation surrounding upcoming alopecia areata trial readouts. While the community is actively debating the stock's potential for a buyout or partnership given its pipeline potential, conversation is also heavily focused on navigating recent volatility and the impact of a capital raise.

Sezzle, Inc. engages in the operation of a digital payment platform that enables bank-to-bank transfer of money between consumers and businesses. The company was founded by Charlie G. Youakim, Killian Brackey and Paul V. Paradis on January 4, 2016 and is headquartered in Minneapolis, MN.

Sezzle Inc.

Sezzle is seeing intense investor debate as a sharp post-earnings pullback collides with high short interest, with bulls highlighting its strong fundamentals and share buyback program while bears point to governance concerns and valuation risks. Market participants are closely watching for signs of a squeeze as the company pivots to a "super app" model, leading to speculative activity around institutional accumulation and potential upside momentum.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

The Roundhill Magnificent Seven ETF is currently in focus as investors analyze the group's critical role in market breadth following a period of technical consolidation and mixed earnings reactions. Community sentiment is largely divided between concerns over AI-related capital expenditure sustainability and bullish expectations that mega-cap leadership will drive a year-end rally as the market seeks stability amid shifting macroeconomic conditions.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is trending as community members rally around its ecosystem and staking yields, while investors closely monitor technical support levels amid broader crypto market volatility. Discussions are heavily focused on the resilience of the network, the potential for long-term growth, and the accumulation of various Solana-based tokens despite fluctuating sentiment.

Goodyear Tire & Rubber Co. engages in the development, manufacture, distribution, and sale of tires. It operates through the following geographical segments: Americas, Europe, Middle East, and Africa, and Asia Pacific. The Americas segment is involved in the development, manufacture, distribution, and sale of tires and related products and services in North, Central, and South America. The Europe, Middle East, and Africa segment focuses on the development, manufacture, distribution, and sale of tires for automobiles, trucks, buses, aircraft, motorcycles, earthmoving, mining, and industrial equipment throughout Europe, the Middle East, and Africa. The Asia Pacific segment refers to the development, manufacture, distribution, and sales of tires for automobiles, trucks, buses, aircraft, farm, earthmoving, mining, and industrial equipment throughout the Asia Pacific region. The company was founded by Frank A. Seiberling on August 29, 1898 and is headquartered in Akron, OH.

Goodyear Tire & Rubber Co.

Goodyear Tire & Rubber is attracting significant attention as investors anticipate a turnaround driven by the 'Goodyear Forward' restructuring plan, while recent community discussions highlight the stock as a potential undervalued opportunity despite broader economic pressures. Traders are actively monitoring potential volatility ahead of upcoming earnings, with increased call option activity suggesting some market participants are betting on a sharp move.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is seeing a surge in investor interest driven by momentum in its weight-loss peptide offerings and potential regulatory milestones. While bullish sentiment is bolstered by recent analyst upgrades and strong price action, the community remains divided between those anticipating a short squeeze and skeptics wary of the stock's historical volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (Satellos or the Company), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today...

Halper Sadeh LLC Encourages DHIL, GBIO, CTGO Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages DHIL, GBIO, CTGO Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages DHIL, GBIO, CTGO Shareholders to Contact the Firm to Discuss Their...

Halper Sadeh LLC Encourages CTGO, GBIO, CDE Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages CTGO, GBIO, CDE Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages CTGO, GBIO, CDE Shareholders to Contact the Firm to Discuss Their...

Halper Sadeh LLC Encourages QIPT, FITB, GBIO, APLT Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages QIPT, FITB, GBIO, APLT Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages QIPT, FITB, GBIO, APLT Shareholders to Contact the Firm to...

Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Dr. Jeffrey...

Generation Bio Stock Surged 31% Pre-Market Today – What’s Going On?

Equity

Generation Bio on Tuesday said that it is evaluating strategic alternatives to maximize the value of its assets for shareholders and implementing a strategic restructuring expected to result in a 90% reduction in workforce. 


Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates

Generation Bio (GBIO) delivered earnings and revenue surprises of -11.43% and -51.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Beats Revenue Estimates

Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of +1.96% and +16.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates

Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA, a novel cell-targeted lipid nanoparticle delivery system, or ctLNP, and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.

Generation Bio Co

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.11	--	--	N/A
Q4 '25	-$7.83	--	--	N/A
Q3 '25	-$3.15	-$0.82	73.97%	BEAT
Q2 '25	-$2.85	-$3.12	-9.53%	MISSED
Q1 '25	-$0.29	-$2.20	-667.74%	MISSED

GBIOGeneration Bio Co

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest GBIO News